IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1632

Examiner: R. Shukla

In re the application of: Hermann Bujard et al.

Serial No.: 09/777,317

Filed: February 5, 2001

For: TETRACYCLINE-REGULATED

TRANSCRIPTIONAL ACTIVATOR FUSION

PROTEINS

Attorney Docket No.: BBI-013C3CN3

MS Sequence

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATION UNDER 37 CFR 1.10	
Date of Deposit: March 15, 2004	Mailing Label Number: EL 935 342 668 US
I hereby certify that this 37 CFR 1.53(d) request and the documents referred to therein as enclosed are being deposited with the United States Postal Service on the date indicated above in an envelope as "Express Mail Post Office to Addressee" service under 37 CFR 1.10 and addressed to MS Sequence, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, Washington, D.C. 20231.	
DeAnn F. Smith, Esq. Name of Person Mailing Paper	Signature of Person Mailing Paper

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURE

Dear Sir:

This is an amendment and response to the Office Communication mailed from the Patent Office on January 15, 2004. A substitute sequence listing is also being submitted herewith. Amendments to the specification are shown on page 2 of this amendment and response. Remarks begin on page 3 of this paper. Please amend the above-referenced application as follows: